Abstract
ABCG2, or breast cancer resistance protein (BCRP), is an ATP-binding cassette half-transporter that has been shown to transport a wide range of substrates including chemotherapeutics, antivirals, antibiotics and flavonoids. Given its wide range of substrates, much work has been dedicated to developing ABCG2 as a clinical target. But where can we intervene clinically and how can we avoid the mistakes made in past clinical trials targeting P-glycoprotein? This review will summarize the normal tissue distribution, cancer tissue expression, substrates and inhibitors of ABCG2, and highlight the challenges presented in exploiting ABCG2 in the clinic. We discuss the possibility of inhibiting ABCG2, so as to increase oral bioavailability or increase drug penetration into sanctuary sites, especially the central nervous system; and at the other end of the spectrum, the possibility of improving ABCG2 function, in the case of gout caused by a single nucleotide polymphism. Together, these aspects of ABCG2/BCRP make the protein a target of continuing interest for oncologists, biologists, and pharmacologists.
Keywords: ABCG2/BCRP, blood-brain barrier, CNS penetration, drug resistance, gout, oral bioavailability, Q141K, single nucleotide polymorphism, cancer, P-glycoprotein, sanctuary sites, MXR, gene amplification, gene expression, promiscuous transporter
Current Pharmaceutical Biotechnology
Title: The Challenge of Exploiting ABCG2 in the Clinic
Volume: 12 Issue: 4
Author(s): Robert W. Robey, Caterina Ierano, Zhirong Zhan and Susan E. Bates
Affiliation:
Keywords: ABCG2/BCRP, blood-brain barrier, CNS penetration, drug resistance, gout, oral bioavailability, Q141K, single nucleotide polymorphism, cancer, P-glycoprotein, sanctuary sites, MXR, gene amplification, gene expression, promiscuous transporter
Abstract: ABCG2, or breast cancer resistance protein (BCRP), is an ATP-binding cassette half-transporter that has been shown to transport a wide range of substrates including chemotherapeutics, antivirals, antibiotics and flavonoids. Given its wide range of substrates, much work has been dedicated to developing ABCG2 as a clinical target. But where can we intervene clinically and how can we avoid the mistakes made in past clinical trials targeting P-glycoprotein? This review will summarize the normal tissue distribution, cancer tissue expression, substrates and inhibitors of ABCG2, and highlight the challenges presented in exploiting ABCG2 in the clinic. We discuss the possibility of inhibiting ABCG2, so as to increase oral bioavailability or increase drug penetration into sanctuary sites, especially the central nervous system; and at the other end of the spectrum, the possibility of improving ABCG2 function, in the case of gout caused by a single nucleotide polymphism. Together, these aspects of ABCG2/BCRP make the protein a target of continuing interest for oncologists, biologists, and pharmacologists.
Export Options
About this article
Cite this article as:
W. Robey Robert, Ierano Caterina, Zhan Zhirong and E. Bates Susan, The Challenge of Exploiting ABCG2 in the Clinic, Current Pharmaceutical Biotechnology 2011; 12 (4) . https://dx.doi.org/10.2174/138920111795163913
DOI https://dx.doi.org/10.2174/138920111795163913 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
5-HT3 Receptors: A Potential Therapeutic Target for Epilepsy
Current Neuropharmacology Radioactive Nanoparticles and their Main Applications: Recent Advances
Recent Patents on Nanotechnology Farnesyltransferase Inhibitors: A Comprehensive Review Based on Quantitative Structural Analysis
Current Medicinal Chemistry Biological Activities of Carlina Oxide Isolated from the Roots of Carthamus caeruleus
The Natural Products Journal Anti Tumor Necrosis Factor-a Monoclonal Antibody (Infliximab) Therapy in Patients with Inflammatory Bowel Disease (IBD): Applications and Side Effects
Drug Design Reviews - Online (Discontinued) Conditionally Replicating Adenoviruses for Cancer Treatment
Current Cancer Drug Targets Inflammation and Pancreatic Cancer: Recent Development with Focusing on Potential New Drug Targets
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Possibilities of Poly(D,L-lactide-co-glycolide) in the Formulation of Nanomedicines Against Cancer
Current Drug Targets Baicalin-induced Cytotoxicity and Apoptosis in Multidrug-resistant MC3/5FU Mucoepidermoid Carcinoma Cell Line
Letters in Drug Design & Discovery 5-HT3 Receptors
Current Drug Targets - CNS & Neurological Disorders Nutrient Regulation of Tumor and Vascular Endothelial Cell Proliferation
Current Cancer Drug Targets Development and Applications of Optical Imaging Techniques in Cancer Diagnosis: Diffuse Optical Tomography and Microendoscopy
Current Medical Imaging Global View on Rare Diseases: A Mini Review
Current Medicinal Chemistry Surgical Approach to Ulcerative Colitis: When is the Best Timing after Medical Treatment?
Current Drug Targets Computational Methods and Algorithms for Mass-Spectrometry Based Differential Proteomics
Current Proteomics Ethnic Differences in Pharmacogenetically Relevant Genes
Current Drug Targets Anticancer Drug Discovery using Chemical Genomics
Current Medicinal Chemistry Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Development of Cancer Vaccine Targeting WT1 Product which is Expressed in Various Kinds of Malignant Neoplasms
Medicinal Chemistry Reviews - Online (Discontinued) The Stem Cell Niche as a Pharmaceutical Target for Prevention of Skeletal Metastases
Anti-Cancer Agents in Medicinal Chemistry